Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.38 |
| ▸ | FNTB | P49356 | 14/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 14/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592792 | 0.89 | HRH1 (0.41) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL3500628 | 0.86 | FNTA (0.54) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL7593498 | 0.84 | FNTA (0.36) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL7593432 | 0.84 | FNTA (0.36) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL7118951 | 0.84 | FNTA (0.36) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL7183666 | 0.84 | FNTA (0.57) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL7128886 | 0.84 | FNTA (0.36) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL7127275 | 0.84 | FNTA (0.36) | FNTAFNTBPGGT1BHRH1HTR1A | |
| SCHEMBL7156162 | 0.84 | CYP19A1 (0.42) | HRH3CYP19A1 | |
| SCHEMBL7132213 | 0.84 | PDK2 (0.37) | HRH3GPR119CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | claimed |
| US-6355643-B1 | ENZYME INHIBITORS, RAS GENES AND PROTEINS | MERCK & CO., INC. | 2002-03-12 | — | — | US | claimed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| US-6355643-B1 | ENZYME INHIBITORS, RAS GENES AND PROTEINS | MERCK & CO., INC. | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | FNTA 2/4885FNTB 7/4885PGGT1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.